Last updated 2026-07-22
- Raised Undisclosed Round led by Youdim Pharmaceuticals, Nov 2020
Total raised
—
Last: Undisclosed Round 2020-12
Stage
Seed
Founded
2020
Headcount
6
HQ
Yokne'am Illit, Israel
Sector
Health Tech & Life Sciences
About
Exegiline Pharma is developing MT-031, a novel multifunctional oral drug for the treatment of dementia and Alzheimer's disease. MT-031 combines rivastigmine (Exelon) and rasagiline (Azilect) moieties, acting as a dual acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitor, as well as a selective irreversible inhibitor of MAO-A. It also possesses anti-inflammatory, neuroprotective, and cognitive/memory-enhancing activities. The company was established at Youdim Pharmaceuticals, a pharmaceutical company and incubator.
Funding history · 1 round · — total
2020-11
Undisclosed Round
Undisclosed
★ Youdim Pharmaceuticals
Headcount over time
From 6 (2021-02) to 1 (2022-03) · -5 (-83%) · 2 points · source: Finder history + radar grounding
Q&A
- What is Exegiline Pharma's primary focus?
- Exegiline Pharma is focused on the multifactorial treatment of Alzheimer's Disease, developing a novel multifunctional oral drug called MT-031.
- What is the mechanism of action for Exegiline Pharma's drug candidate MT-031?
- MT-031 acts as a dual acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitor, and also provides selective irreversible inhibition of MAO-A. It also exhibits anti-inflammatory, neuroprotective, and cognitive- and memory-enhancing activities.
- When was Exegiline Pharma founded?
- Exegiline Pharma was founded in December 2020.
- How many employees does Exegiline Pharma currently have?
- Exegiline Pharma has 1-10 employees.
- Has Exegiline Pharma secured any patents for its technology?
- Yes, Exegiline Pharma's molecule and its indications are protected by US and European patents.
- Who are the founders of Exegiline Pharma?
- The founders of Exegiline Pharma include Tal Youdim (Chairman), Dr. Santiago Ini (CEO), Prof. Moussa Youdim (Founder), and Prof. Eli Heldman (CSO, Director).
- What is Exegiline Pharma's current stage of development?
- Exegiline Pharma is currently in the Seed stage and its product is in the R&D stage.
- Which investor participated in Exegiline Pharma's funding round in December 2020?
- Youdim Pharmaceuticals participated in Exegiline Pharma's funding round in December 2020.
Team · 1
Prof. Moussa Youdim
Founder · Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
drug-developmentparkinsonoral-drugspharma-companiesneurologybrain-disordertreatmentsdegenerative-diseasespharmaceuticalsalzheimers-disease
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | www.Exegiline.com |
|---|
Identifiers & details
| Founded | 2020-12 |
|---|---|
| Employees (exact) | 6 |
Radar intelligence
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516301991 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2020-12-27 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | yes |
| Last annual report | 2024 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | הכרמל 6 קריית טבעון |